AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alvotech shares rise 1.46% premarket after receiving European approval for Mynzepli®.
ByAinvest
Thursday, Aug 21, 2025 4:50 am ET1min read
Alvotech rose 1.46% in premarket trading, driven by the news that Advanz Pharma and Alvotech received European approval for Mynzepli® (aflibercept) for the treatment of various retinal diseases. This approval is based on comprehensive analytical, non-clinical, and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD. Additionally, Alvotech appointed Patrik Ling as VP of Investor Relations Scandinavia, bringing over 25 years of experience in the life-science industry.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet